Anti-Heparin-Platelet Factor 4 Antibody is a Risk Factor for Vascular Access Obstruction in Patients Undergoing Hemodialysis.
10.3346/jkms.2003.18.1.69
- Author:
Eun Young LEE
1
;
Kyu Yoon HWANG
;
Jong Oh YANG
;
Sae Yong HONG
Author Information
1. Department of Internal Medicine and Clinical Research Institute, Soonchunhyang University Chonan Hospital, Chonan, Korea. syhong@schch.co.kr
- Publication Type:Original Article
- Keywords:
Anti-Heparin-Platelet Factor 4 Antibody;
Renal Dialysis;
Vascular Access Obstruction;
Kidney Failure;
Chronic
- MeSH:
Adult;
Autoantibodies/immunology*;
Autoimmune Diseases/immunology*;
Catheters, Indwelling*;
Enzyme-Linked Immunosorbent Assay;
Female;
Heparin/immunology*;
Human;
Kidney Failure, Chronic/blood;
Kidney Failure, Chronic/immunology;
Kidney Failure, Chronic/therapy*;
Male;
Middle Aged;
Platelet Factor 4/immunology*;
Recurrence;
Renal Dialysis*;
Risk Factors;
Thrombophilia/immunology*;
Thrombosis/epidemiology*;
Thrombosis/immunology;
Thrombosis/prevention & control
- From:Journal of Korean Medical Science
2003;18(1):69-72
- CountryRepublic of Korea
- Language:English
-
Abstract:
Since heparin is an anticoagulant commonly used in hemodialysis and the patients on hemodialysis are repeatedly exposed to heparin, heparin may be the cause of the development of heparin-dependent antibodies and thrombotic complications in patients on hemodialysis. The purpose of this study was to determine the prevalence and the clinical significance of the antibodies against heparin-platelet factor 4 complexes as determined by enzyme immunoassay in patients on maintenance hemodialysis. The prevalence of anti-heparin-platelet factor 4 antibodies was higher in hemodialysis patients than in normal subjects (8.8 vs 0.0%, p<0.05). The number of past episodes of vascular access obstruction per year was significantly higher in the anti-heparin-platelet factor 4 antibody positive group than antibody negative group. Anti-heparin-platelet factor 4 antibody positive patients experienced more frequent vascular access obstructions than control subjects. In conclusion, anti-heparin-platelet factor 4 antibody might be a risk factor for vascular access obstructions in patients with end-stage renal disease on maintenance hemodialysis.
